about
Mechanism of Inhibition of the GluA2 AMPA Receptor Channel Opening: the Role of 4-Methyl versus 4-Carbonyl Group on the Diazepine Ring of 2,3-Benzodiazepine Derivatives.Mechanism and site of inhibition of AMPA receptors: substitution of one and two methyl groups at the 4-aminophenyl ring of 2,3-benzodiazepine and implications in the "E" site.Peptide-based proteasome inhibitors in anticancer drug design.Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.Synthesis and biological evaluation of papain-family cathepsin L-like cysteine protease inhibitors containing a 1,4-benzodiazepine scaffold as antiprotozoal agents.Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs).Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors.Nonpeptidic vinyl and allyl phosphonates as falcipain-2 inhibitors.Synthesis and molecular modeling studies of derivatives of a highly potent peptidomimetic vinyl ester as falcipain-2 inhibitors.Design and synthesis of novel isoxazole-based HDAC inhibitors.Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors.Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain.Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors.Development of rhodesain inhibitors with a 3-bromoisoxazoline warhead.Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors.Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis.Mechanism of falcipain-2 inhibition by α,β-unsaturated benzo[1,4]diazepin-2-one methyl ester.Identification of a new series of amides as non-covalent proteasome inhibitors.Synthesis and Pharmacological Evaluation of α4β2Nicotinic Ligands with a 3-Fluoropyrrolidine NucleusEfficient synthesis of novel glutamate homologues and investigation of their affinity and selectivity profile at ionotropic glutamate receptorsSynthesis of (3-hydroxy-pyrazolin-5-yl)glycine based ligands interacting with ionotropic glutamate receptorsNMR characterization and conformational analysis of a potent papain-family cathepsin L-like cysteine protease inhibitor with different behaviour in polar and apolar mediaDevelopment of peptidomimetic boronates as proteasome inhibitorsSelected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activitiesDevelopment of Novel Peptidomimetics Containing a Vinyl Sulfone Moiety as Proteasome InhibitorsPeptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitorsNovel Peptidomimetic Cysteine Protease Inhibitors as Potential Antimalarial AgentsDrug combination studies of curcumin and genistein against rhodesain of Trypanosoma brucei rhodesienseEvaluation of curcumin irreversibilityOptimization Strategy of Novel Peptide-Based Michael Acceptors for the Treatment of Human African TrypanosomiasisNon-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma MM.1R cellsDevelopment of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes
P50
Q34068562-B85763E7-373F-439D-9BCF-E6CA74F080F7Q35628865-12C442BF-14B7-4E1B-A735-C0B528849877Q38192572-65D0D2CC-8C94-40EE-94FF-B6BC142EEC0FQ38982918-A6ED3A28-9720-4D8B-8ED1-09347BAD0DE1Q38985765-E10E9BCA-48B0-4238-9D1F-DD8B0E6F52D9Q38988876-4FEF4AA6-042A-4F44-BA41-78639B572A8BQ39368534-7764E94C-AB62-4B93-8E22-6F2E99171CEEQ39871302-2FA12023-9141-460E-9272-D182A873FD74Q42167513-EFCC4378-F0C3-4B62-A48D-AB313E80BB3FQ42717133-FE80CDA9-C5DB-426D-847D-2E0048105F2FQ42967812-5640CFD4-9FCD-403D-B1D7-AB270823014AQ42991352-D02C07F7-EC5E-4699-A2FD-BEA73A62054DQ43077558-F8525224-4CB8-4AB3-8C08-E5195DA2F4A9Q43285388-6479C4E8-CB9A-4601-A394-DDBCAAC2F78FQ46636439-D1143734-CE3E-4FAC-90D9-0B42ABF5D4E4Q46783287-F21A10E4-C4FB-4104-AE75-85365C3E0CCDQ46787191-07C66B61-8E44-420A-8BE0-F94E2F0F72DFQ50503846-5DB57D65-C083-4E3D-B7D6-D498AF7A775CQ51751951-07B86168-EF9D-49BF-BD04-16E1313032C2Q58853249-77DD1FCE-84B9-4E05-A15E-7CF08471EAF6Q58853253-27E3C812-DB24-46D4-ACAE-400C7B583C6DQ58853254-6E588DE7-8CD7-4B8A-986A-6622CA38611CQ58853568-1E2D9727-723C-4648-9DF2-DCCF37ACE6C1Q58855688-FBF308D6-7DB3-4544-8FC2-B1B9977A457BQ58856043-3D2C70EF-CEC1-4F27-88EB-FBC530931E9DQ58862067-DEFD8AA4-B818-4BD2-B6A0-1AF6C88DB5ACQ58862073-96A734F1-650C-4CDC-8C8F-35B65A2EB55FQ58862082-7CF6DB1B-2929-4383-8B82-C5C0A9F0FF2AQ89087555-4F871C46-E5F1-44D2-97D3-E6BB90CBEC8AQ91195582-20A0C963-1447-48B2-A5DB-3525688AEE31Q91244105-5CDAF991-22AA-4409-8C69-5ABCA177D827Q91893450-B5EB9A05-6D06-4B4B-8DCD-6B33B6A8DB94Q92097112-DAF22737-F931-44B6-ACBD-345D2AA32631
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Roberta Ettari
@ast
Roberta Ettari
@en
Roberta Ettari
@es
Roberta Ettari
@nl
Roberta Ettari
@sl
type
label
Roberta Ettari
@ast
Roberta Ettari
@en
Roberta Ettari
@es
Roberta Ettari
@nl
Roberta Ettari
@sl
prefLabel
Roberta Ettari
@ast
Roberta Ettari
@en
Roberta Ettari
@es
Roberta Ettari
@nl
Roberta Ettari
@sl
P106
P1153
13908046800
P21
P31
P496
0000-0001-9020-2068